On November 18, 2025, Cullinan Therapeutics, Inc. announced the termination of a patent license agreement with MIT for the cancer immunotherapy product CLN-617, effective February 18, 2026, as they decided not to pursue further development of the product. This termination will return the licensed patent rights back to MIT.